Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5748463 | 0.93 | HSP90AB1 (0.50) | HSP90AB1KMT2AKDM4EHSP90AA1CYP2D6 | |
| SCHEMBL3209557 | 0.79 | HTR6 (0.36) | HRH4HTR6 | |
| SCHEMBL3188454 | 0.78 | HTR6 (0.38) | HRH4HTR6 | |
| SCHEMBL10617507 | 0.73 | HSP90AB1 (0.60) | HSP90AB1KMT2AKDM4EHSP90AA1CYP2D6 | |
| SCHEMBL4716506 | 0.72 | HRH4 (0.38) | HRH4MAPT | |
| SCHEMBL601156 | 0.72 | HRH3 (0.65) | HRH4 | |
| SCHEMBL4410427 | 0.71 | DHFR (0.33) | HRH4HTR6 | |
| SCHEMBL7420125 | 0.71 | HSP90AB1 (0.58) | HSP90AB1KMT2AKDM4EHSP90AA1CYP2D6 | |
| Hydrochloric Acid SCHEMBL10618220 | 0.71 | HSP90AB1 (0.58) | HSP90AB1KMT2AKDM4EHSP90AA1CYP2D6 | |
| SCHEMBL15103664 | 0.71 | HRH4 (0.40) | HRH4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | UCB PHARMA, S.A. (BE) | 2010-02-11 | — | — | US | claimed |
| EP-2066645-A2 | 2 AMINO-PYRIMIDINE DERIVATIVES AS H4 RECEPTOR ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | UCB Pharma S.A. (BE) | 2009-06-10 | — | — | EP | claimed |
| WO-2008031556-A2 | 2 AMINO-PYRIMIDINE DERIVATIVES AS H4 RECEPTOR ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | UCB PHARMA, S.A. (BE) | 2008-03-20 | — | — | WO | claimed |
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | UCB PHARMA, S.A. (BE) | 2010-02-11 | — | — | US | disclosed |
| EP-2066645-A2 | 2 AMINO-PYRIMIDINE DERIVATIVES AS H4 RECEPTOR ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | UCB Pharma S.A. (BE) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008031556-A2 | 2 AMINO-PYRIMIDINE DERIVATIVES AS H4 RECEPTOR ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | UCB PHARMA, S.A. (BE) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | HRH4, HRH2, HRH3 | HSP90AB1 3838/4885KMT2A 795/4885KDM4E 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.